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Background We recently demonstrated in a randomized, double-blind, placebo-
controlled trial that intramyocardial bone marrow cell (BMC) injection is associated with 
improvements in myocardial perfusion and anginal symptoms in chronic myocardial 
ischemia patients. In the present study the results of the cross-over phase of this trial, 
in which patients previously treated with placebo received autologous BMC injections 
are reported. This allows a unique intra-patient comparison on the effect of BMC versus 
placebo injection with elimination of patient-related confounding factors. 
Methods In sixteen patients (14 male, 64±10 years), who previously received 
intramyocardial placebo injections in the setting of a randomized trial, 100x106 BMC 
were injected using the NOGA-system. Canadian Cardiovascular Society (CCS) angina 
score and quality of life were evaluated at baseline, 3 and 6 months. Tc-99m single-
photon emission computed tomography (SPECT) and magnetic resonance imaging were 
performed at baseline and 3 months to assess myocardial perfusion and left ventricular 
(LV) function. 
Results CCS score and quality of life improved significantly after BMC injection as 
compared to placebo (P=0.01 and P=0.02, respectively). SPECT revealed a significant 
greater improvement (p=0.03) in summed stress score after BMC injection as compared 
to placebo. LV end-systolic volume significantly decreased after BMC injection but not 
after placebo injection. LV end-diastolic volume and LV ejection fraction did not change. 
Conclusion Intramyocardial BMC injection in patients with chronic myocardial ischemia 
who previously received intramyocardial placebo treatment resulted in significant 
improvement in angina symptoms and myocardial perfusion. These results confirm the 
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INTRODUCTION
Despite optimal medical treatment and advanced revascularization strategies, a growing 
number of patients suffer from severe coronary artery disease resulting in chronic 
myocardial ischemia and disabling angina, not amenable to conventional treatment 
options. Bone marrow cell (BMC) injection has emerged as a potential therapeutic option 
to improve myocardial perfusion, left ventricular (LV) function and accompanying 
anginal symptoms, in patients with chronic ischemic heart disease1. 
We previously reported the results of a double-blind placebo-controlled randomized trial 
in which we evaluated the efficacy of autologous bone marrow-derived mononuclear cell 
injection into the ischemic myocardium of patients with refractory angina2. At 3 months 
follow-up improvements in myocardial perfusion and LV function were observed as 
well as a decrease in anginal symptoms2. In line with these findings, a recently published 
randomized placebo-controlled trial reported improvements in angina frequency and 
exercise tolerance at 12 months follow-up after intramyocardial injection of CD34+ 
cells3. Furthermore, at 6 and follow-up improvements in stress perfusion were observed. 
Although the results of these medium-sized trials confirmed the findings of non-
randomized pilot studies4-7, 2 small-sized randomized studies yielded discordant results 
and documented only limited or no improvement in myocardial perfusion and anginal 
complaints2, 8, 9. 
The observed differences may be related to a variety of factors, including cell isolation 
protocols10, cell type11 and dose8, 12. In addition, patient-specific characteristics such as 
comorbidity, genetic profile and cellular response to BMC administration may influence 
treatment effect. Therefore, unknown confounding factors may influence treatment 
outcome, especially since the exact mechanism by which bone marrow cells may improve 
myocardial perfusion and function is only partially understood.
After completion of the randomized trial, patients which were initially treated with 
placebo injection were offered to enter the cross-over phase of the trial to receive 
intramyocardial BMC injection. Therefore, this cross-over phase allows an intra-patient 
comparison of BMC injection and placebo treatment with a minimum of patient-specific 
confounding factors. Consequently, the aim of the current study was to assess the effect 
of BMC injection in the same patients with chronic myocardial ischemia that previously 
received placebo treatment Furthermore, the results of the cross-over phase were 












































The study population consisted of patients who received placebo injection in the 
previously described randomized, double-blind, placebo-controlled trial.[2] All 
patients had severe angina (Canadian Cardiovascular Society (CCS) class II, III or IV) 
despite optimal medical therapy, and stress-inducible ischemia on technetium-99m 
tetrofosmin single-photon emission computed tomography (SPECT) without options for 
conventional revascularization. Exclusion criteria were left ventricular ejection fraction 
(LVEF) less than 35%, acute myocardial infarction within 6 months before enrollment, 
history of malignancy, renal dysfunction or unexplained haematological or biochemical 
abnormalities. The institutional ethics committee approved the protocol, and all 
patients provided written informed consent. A detailed study protocol and results of 
the randomized, double-blind, placebo-controlled trial have been reported previously2. 
The study was registered at the Dutch trial registry (www.trialregister.nl, no. NTR400/
ISRCTN58194927). 
Study design and protocol
The current study was designed as an intra-patient comparison to compare the effect 
of autologous mononuclear BMC injection with the effect of a previously administered 
placebo injection in patients with chronic myocardial ischemia. As such, each patient 
served as his own control. Placebo injections were performed in the setting of a 
randomized, double-blind, placebo controlled trial of which the results have been 
recently published2. 
The study protocol of the trial has been previously reported2. In the cross-over phase, 
clinical and functional assessment at baseline and follow-up, as well as the injection 
procedure, were identical to the main trial. In brief, the study protocol was as follows: 
At least twelve months after placebo injection, eligibility for cross-over treatment was 
determined using the inclusion and exclusion criteria of the original trial. At baseline, 
the clinical status was assessed according to the CCS classification, ranging from class 
I (mild) to IV (severe) 13. The disease specific Seattle Angina Questionnaire was used 
to evaluate the patients’ quality of life14, 15. Technetium-99m tetrofosmin SPECT was 
performed to assess myocardial perfusion, and LV function and volumes were assessed 
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Bone marrow was aspirated from the iliac crest under local anesthesia, followed by Ficoll 
density centrifugation to isolate the mononuclear cells. With the use of the NOGA system 
(Biologics Delivery Systems, Johnson & Johnson, Irwindale, California), approximately 
100x106 autologous bone marrow-derived mononuclear cells were injected at myocardial 
regions with stress-inducible ischemia on SPECT4. 
At 3 months and 6 months follow-up, the clinical status (CCS and quality of life) was 
reassessed. Technetium-99m tetrofosmin SPECT and MRI were repeated after 3 months to 
evaluate myocardial perfusion and LV function, respectively. To monitor the occurrence 
of arrhythmias, 24-hour Holter electrocardiogram recordings were obtained at 6 weeks 
and 6 months follow-up.
SPECT imaging 
Technetium-99m tetrofosmin SPECT imaging was performed using a two-day stress-
rest protocol as previously described.[4] Briefly, the stress protocol included adenosine 
infusion (0.14 mg/kg/min) for 6 minutes and intravenous injection of 500MBq Tc-
99m tetrofosmin after 3.5 minutes of adenosine. Rest images were obtained using an 
injection of 500 MBq technetium-99m tetrofosmin. In order to analyze the myocardial 
perfusion, a standard short- and long-axis projection, perpendicular to the heart axis, 
was reconstructed, which were adjusted for peak myocardial activity (100%).
The myocardium was divided into 17 segments according to the American Heart 
Association/American College of Cardiology recommendations16. To analyze myocardial 
perfusion, Quantitative Gated SPECT software (QGS software, Cedars-Sinai Medical 
Center, Los Angeles, California) was used and segmental tracer activity was categorized 
on a 4-point scale: 1 = normal tracer activity >75%; 2 = tracer activity 50% to 75%; 3 = 
tracer activity 25% to 49%; and 4 = tracer activity <25%.
Significant fill-in (>10%) of perfusion defects, observed on the images at rest, was 
classified as ischemic myocardium. By summation of the patients’ segmental scores 
at stress and rest, the summed stress score and summed rest score, respectively, were 
calculated17. 
Magnetic resonance imaging
Assessment of the parameters of global systolic function was performed by MRI studies, 
using a 1.5-Tesla system (Philips medical Systems; Best, the Netherlands) with a 5-segment 










































of view 400x400 mm2, matrix size 256x256 pixels) was used to image the heart in the 
short-axis view during 15 second breath holds. To determine LV volumes and LVEF, 
previously validated software (QMass MR, Medis Medical Imaging Systems; Leiden, the 
Netherlands)[18] was used. The images were analyzed by two experienced observers 
(J.v.R. and S.F.R), blinded to all clinical data. The intra- and inter-observer variability 
were 1±3 ml and 2±4 ml for LV end-systolic volume (LVESV), 1±4 ml and 2±6 ml for LV 
end-diastolic volume (LVEDV), and 0.2±1.6% and 0.5±2.1% for LVEF4. 
Statistical analysis 
All analyses were performed according to the intention-to-treat principle. Complete case 
analysis was performed for all paired tests. Data are reported as mean±SD. An intra-
patient comparison was conducted comparing patients after placebo treatment and 
cross-over BMC treatment. Continuous data were compared using a Wilcoxon signed 
rank test. Categorical data were compared using a χ2-test or Fisher exact test. We applied 
repeated measures analysis of variance and the Friedman test to compare the change 
in distribution of continuous outcome data after cross-over and placebo treatment, 
at baseline and follow-up. A Mann-Whitney test was used to compare changes in 
semiquantitative data. A P-value of less than 0.05 was considered statistically significant. 
All statistical analyses were performed with SPSS software version 17.0 (SPSS, Chicago, 
Illinois).
RESULTS
In the previously reported trial[2], twenty five patients were randomly assigned to placebo 
treatment. Of these patients, 9 patients were not eligible for cross-over treatment since 
they did not meet the inclusion criteria. Therefore, 16 patients (age 64±10, male 14) were 
enrolled in the current evaluation. Since the current study comprised an intra-patient 
comparison, baseline patient characteristics were identical in both treatment groups 
apart from baseline age and changes which occurred after placebo treatment (Table 1). 
In all patients, the type and dose of antianginal medication remained unchanged during 
the study period of a given treatment. Between both treatments only minimal changes in 
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Table 1. Baseline characteristics
Baseline characteristics Placebo (n=16) Cross-over (n=16) P-value
Age, years 62±10 64±10 <.00
Men 14(88) 14(88) 1.00
Body mass index, kg 30±5 30±5 1.00
Cardiovascular risk factors, n(%)
   Smoking 5(31) 5(31) 1.00
   Hypertension 8(50) 8(50) 1.00
   Diabetes 5(31) 5(31) 1.00
   Dyslipidemia 8(50) 8(50) 1.00
   Family history of CAD 8(50) 8(50) 1.00
Current medication, n(%)
   Nitrates 14(88) 14(88) 1.00
   B-blockers 15(93) 15(93) 1.00
   Calcium channel Blockers 12(75) 13(81) 0.32
   Statins 16(100) 16(100) 1.00
   ACE-inhibitors 10(63) 10(63) 1.00
   Clopidogrel 6(38) 5(31) 0.32
   Aspirin 13(81) 13(81) 1.00
   Oral anticoagulants 2(13) 2(13) 1.00
History, n(%)
   Prior MI 12(75) 11(75) 1.00
   Prior CABG 10(63) 10(63) 1.00
   Prior PCI 8(50) 9(56) 0.32
Procedural and safety data
Mean procedural time for mapping and injection was 53±15 minutes during cross-over 
treatment and 50±14 minutes during placebo treatment (P=0.67). During cross-over 
patients received 8.5±1.4 injections, whereas during placebo treatment, patients received 
8.1±0.9 injections (P=0.31). Injections of approximately 0.2 to 0.3 ml cell suspension or 
placebo were delivered at each injection site. The cell suspension as injected during 
cross-over treatment contained a total of 100 x106 bone marrow mononuclear cells, with a 
CD34-positive cell fraction of 1.9%±1.2%. Compared to cross-over treatment, the primary 
treated cell group underwent a comparable cell harvesting procedure followed by 8.5±1.3 
injections (vs. cross-over P=NS) with a similar cell suspension (98 x106 bone marrow cells 
[vs. cross-over P=NS], CD34-positive cell fraction 2.4±0.9% [vs. cross-over P=NS]).
In all patients, intramyocardial injection was performed without major periprocedural 
complications. During 6 months follow-up, no arrhythmias were observed in any of the 










































Two weeks after BMC injection, 1 patient died due to sepsis caused by bilateral 
pneumonia. Safety data from placebo treatment have been published previously.[2]
Myocardial perfusion and ischemia
For both treatment modalities, SPECT images at baseline and 3 months follow-up were 
available in all surviving patients. After cross-over treatment, summed stress score 
improved from 24.7±4.5 at baseline to 21.9±3.9 at 3 months follow-up (P<0.01). After 
placebo treatment, a modest improvement from 24.6±4.8 at baseline to 23.8±5.0 had 
been observed. When the two treatment strategies were compared, the improvements 
in summed stress score were significantly larger after cross-over treatment (treatment 
effect, -2.32; 95% CI, -3.64 to -0.23; P=0.03). As compared to the effect of BMC injection in 
the original trial, the improvement in summed stress score in the cross-over study group 
was similar to the improvement documented in the cell treatment group in the initial 
randomized trial (treatment effect, -0.79; 95% CI, -2.39 to 1.05; P=0.44).
Summed rest score showed a small but significant improvement after cross-over 
treatment (from 21.1±4.1 at to 20.3±3.7, P=0.03), whereas no changes were observed after 
placebo treatment (20.9±4.6 vs. 20.6±4.2 (P=0.18). The changes in summed rest score were 
not significantly different between both treatment phases (P=0.24).
The number of ischemic myocardial segments per patient decreased significantly from 
3.1±2.1 to 1.6±1.4; P<0.01), after cross-over treatment. After placebo treatment, the 
number of ischemic segments also decreased from 3.1±1.6 at baseline to 2.5±1.7 at 3 
months (P=0.02). However, the decrease in ischemic segments was significantly larger 
after cross-over treatment as compared to placebo treatment (treatment effect, -2.36; 95% 
CI, -2.37 to -0.17; P=0.03) (Figure 1).
Myocardial	perfusion	in	injected	and	noninjected	segments
A total of 127 injections was targeted at 60 myocardial segments during cross-over 
(4.0±0.8 injected segments/patient). During placebo treatment, a total of 120 injections 
targeting 57 ischemic segments had been performed (3.8±0.4 injected segments/patient). 
After cross-over treatment, myocardial perfusion score had increased at least 1 point in 
stress or rest perfusion in 50% (30 segments) of the total of 60 injected segments and in 
8% (15 segments) of the total of 195 noninjected segments, after 3 months. After placebo 
treatment, 7 of 57 injected segments (12.3%) revealed improvement after 3 months 
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The percentage of injected segments with an improved perfusion was significantly higher 
after cross-over treatment (P<0.01). No significant difference between both treatments 














Figure 1. Number of ischemic segments as assessed by SPECT
Number of ischemic segments at baseline and 3 months as assessed by SPECT. Comparing placebo 

















Figure 2: Segmental improvement in myocardial perfusion
Segmental improvement in myocardial perfusion score comparing cross-over treatment and 
previous placebo treatment in the same patients. The number of injected segments that improved 











































Paired MRI was performed in 12 patients after cross-over treatment and in 11 patients 
after placebo treatment. After cross-over treatment, a non significant improvement of 
LVEF was observed from 55%±11% at baseline to 57%±12% at 3 months follow-up (P= 
0.10). After placebo treatment, no substantial changes in LVEF were detected (54±10% vs. 
53±10%, P=0.42). The improvement in LVEF was not larger after cross-over treatment as 
compared to the placebo treatment (P=0.12). LVESV decreased significantly after cross-
over treatment but not after placebo. However, the difference in pre- vs. postinjection 
values between treatment modalities was not significantly different (P=0.29). No 
significant changes in LVEDV and LV stroke volume were observed after both treatments 
(Table 2).
Table 2. Left ventricular volumes as assessed by MRI at baseline and follow-up after placebo and 
crossover treatment. 
 Placebo Crossover δBaseline 3 mo P Baseline 3 mo P P
MRI measurements        
 LVEF, % 54±10 53±10 0.42 55±11 57±12 0.10 0.12
 LVEDV, mL 187±56 182±52 0.53 170±42 159±38 0.31 0.57
 LVESV, mL 91±44 89±42 0.53 80±35 73±36 0.04 0.29
 LVSV, mL 97±16 93±14 0.33 90±15 86±12 0.51 0.98
Clinical	outcome	
Clinical status was assessed according to the CCS classification at baseline, 3 months and 
6 months follow-up. After cross-over treatment, a significant improvement was observed 
from 3.1±0.6 at baseline to 2.4±0.8 at 3 months, and to 2.4±0.9 at 6 months (P=0.02). No 
significant improvement in CCS class was observed after placebo injection (2.7±0.6 to 
2.6±0.7 at 3 months, to 2.5±0.6 at 6 months, P=0.52).
Quality-of-life score increased after cross-over treatment from 59±13% to 66±14% at 3 
months, and 69±16% at 6 months (P<0.01). After placebo injections, an improvement 
in quality of life was noted from 59±9% to 62±11% at 3 months and to 62±11% at 6 
months (P<0.01). The improvements in CCS class and quality of life were significantly 
greater after cross-over treatment as compared to placebo treatment (P=0.01 and P=0.02, 
respectively). The effect of cross-over treatment on both CCS class and quality of life were 
not significantly different from the effects of BMC injection in the initial randomized trial 
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Figure 3. Quality-of-life score
Quality-of-life score at baseline and 3 and 6 months follow-up. Comparing the improvement in 
quality of life between cross-over treatment and placebo treatment within the same 16 patients 
demonstrated a significant greater improvement after cross-over treatment. The improvement in 
quality of life after cell injection in the cross-over phase and the randomized trial (24 patients) are 
similar.
DISCUSSION
Key findings of the present study were: 1) autologous BMC injection in patients previously 
treated with placebo is associated with improvements in myocardial perfusion and 
clinical parameters as compared to the previous placebo injection. And 2), these results 
are in line with the findings of the recently reported randomized, double-blind, placebo-
controlled trial which evaluated the efficacy of BMC treatment in patients with chronic 
myocardial ischaemia2. 
Since current revascularization strategies do not suffice in treating the increasing 
population of patients with end-stage ischemic heart disease, cell therapy has been 
introduced as a new treatment modality19, 20. Therapeutic administration of bone marrow 
cells has been suggested to stimulate angiogenesis by the release of growth factors21 
and/or by direct incorporation of cells into new capillaries22, resulting in improvements 










































ischemia severe obstructive coronary artery disease often precludes intracoronary 
delivery of cells, intramyocardial injection of bone marrow cells is the preferred approach 
in these patients. 
Previous studies have indicated the safety and feasibility of intramyocardial BMC 
administration in patients with chronic myocardial ischemia4-7, 23, 24 In line with these 
studies, overall safety assessment in the current trial did not reveal any complications 
considered to be related to cell administration.
The efficacy of BMC treatment in patients with chronic myocardial ischemia has been 
evaluated in several randomized, placebo-controlled trials. Although in general the 
reported findings demonstrate positive effects on myocardial perfusion, function, 
exercise capacity and anginal symptoms, a number of inconsistent findings are present2, 
8, 9 In the small-sized randomized study of Losordo et al8., intramyocardial injection of 
granulocyte-colony stimulating factor (GCSF)-mobilized CD34+ cells did not result in 
significant improvements in angina frequency, exercise capacity or myocardial perfusion. 
However, a larger randomized placebo-controlled trial of the same study group showed 
significant improvements in angina pectoris frequency and exercise tolerance 12 months 
after cell injection3. In addition, myocardial perfusion during stress showed significant 
improvements at 6 months follow-up. The results of the PROTECT-CAD trial[9] showed 
modest improvements in exercise capacity and LVEF after injection of bone marrow-
derived mononuclear cells. Nonetheless, no improvements in anginal complaints or 
myocardial perfusion were observed, although it must be noted that post-hoc analysis 
demonstrated regional improvements in myocardial perfusion in the injected segments. 
In the randomized trial from our group, of which the current study describes the cross-
over phase, 50 patients with chronic myocardial ischemia were assigned to receive 
intramyocardial injection of either bone marrow-derived mononuclear cells or placebo2. 
In this study, BMC injection was associated with improvements in myocardial perfusion, 
LV function and anginal complaints. 
Theoretically, a number of methodological factors may account for the discordant results 
of the aforementioned studies. First, differences in cell isolation and storage protocols 
may affect the functional capacity of the cells, as recently suggested by Seeger et al10. 
Second, cell type and dose varied considerably between these studies, ranging from 
0.5 to 5x105 GCSF-mobilized CD34+ cells in the studies of Losordo to 100 x 106 bone 
marrow-derived mononuclear cells in our trial. Therefore, the potential impact of a dose-
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infarction25, may have influenced treatment effect. Third, group size was substantially 
different in these studies, with the largest treatment groups in the larger randomized 
trial from Losordo et al. (n=53) and our group (n=25), compared to a group size of 9 
or 10 patients in the PROTECT-CAD trial and a group size of 6 patients in the small-
sized study of Losordo et al. Besides the risk of underpowering in the assessment of 
treatment effect, these relatively small group sizes can result in imbalances in baseline 
characteristics. For example, in the PROTECT-CAD trial, diabetes was more prevalent 
in the placebo group. Since it has been suggested that BMC therapy is more effective 
in diabetic patients[26], this imbalance in patient characteristics might theoretically 
confound study results. Similarly, numerous other patient-specific characteristics such 
as genetic variations27, response to medication28 as well as co morbidity28 are known to 
influence treatment outcome in cardiac disease. It is likely that some of these factors 
will impact BMC function, the response of host tissue, and patient prognosis after BMC 
administration, thus modifying the treatment results of BMC injection. As a result, 
outcomes may have been confounded by known and unknown patient-specific factors, 
especially since treatment groups in the described studies were relatively small.
In the current study, an intra-patient comparison model is used, allowing elimination of 
known and unknown patient-specific factors which may possibly confound analysis of the 
treatment effect. Using this design, we observed improvements in myocardial perfusion, 
quality of life and CCS class consistent with the findings of our initial randomized study 
(Figure 3). Of note, the increases in LV ejection fraction and exercise capacity were not 
significant, although there was a trend towards improvements comparable to the effect 
in the initial randomized study. Interestingly, in contrast to findings of the initial trial, 
there was a trend towards a decrease in LVEDV with a decrease in LV stroke volume 
after cross-over treatment. Therefore, the increased LVEF results from a greater decrease 
in LVESV as compared to the decrease in LVEDV. However, because the changes in MRI 
parameters between cross-over and the initial cell-treated group are not significantly 
different, no conclusions can be drawn. (Figure 4.) Overall, the findings of the present 
study confirm the findings of our initial randomized trial using a study design in which 
the number of potential confounding factors is minimized, thereby strengthening the 














































Figure 4: Left ventricular volumes 
 
 
Figure 4: Left ventricular volumes
MRI-derived left ventricular (LV) ejection fraction, LV end systolic volume, LV end diastolic 
volume and LV stroke volume at baseline and 3 months after placebo treatment (11 patients), cross-
over treatment (12 patients) and of the initial bone marrow cell (BMC) treated group (22 patients). 
Comparing the change in MRI parameters between placebo treatment and cross-over treatment 
demonstrates no significant difference. Similarly, the cross-over group shows comparable changes 
as compared to the initial BMC group. 
Limitations
One of the limitations of the current study design was the lack of blinding during the 
cross-over phase that could have led to a placebo effect after BMC injection. Since 
patients were aware of treatment assignment during the cross-over phase, a placebo 
effect cannot be ruled out. However, the placebo effect was at least partially taken into 
account by comparing the results of BMC injection with the effect of (blinded) placebo 
treatment during the initial trial. In addition, there might be a patient bias since in the 
16 cross-over patients placebo treatment resulted in 12.3% improvement of injected cells, 
as compared to 20% the total placebo treated group in the primary study. Therefore, 
the placebo-treated patients included for cross-over may be slightly different from the 
original placebo group. Furthermore, the patient population was small, which may have 
resulted in a lack of statistical power to observe significant differences in LV function and 
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not provide data of long term follow-up on the effects of BMC injection on morbidity 
and mortality.
In conclusion, the results of the study demonstrate that intramyocardial BMC injection 
is associated with a beneficial effect on myocardial perfusion, CCS class and quality of 
life as compared to placebo treatment. Using an intra-patient comparison design, the 
current study confirms the findings of the initial randomized trial, thus strengthening 
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